Skip to main content
Premium Trial:

Request an Annual Quote

Helomics, MDNA Partner on Diagnostics

NEW YORK (GenomeWeb) – Contract research organization Helomics and molecular diagnostics firm MDNA today announced a partnership broadening access to MDNA's tests.

As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets. Helomics will also offer the tests in its CLIA-approved clinical laboratory.

The firms will additionally collaborate on developing, validating, and commercializing other liquid biopsy-based diagnostic tests based on MDNA's Mitomic Technology platform, which exploits unique biological characteristics of mitochondrial DNA. MDNA intends to grant Helomics a license under which Helomics will be able to offer to its pharmaceutical, diagnostic, and biotechnology clients diagnostic tests based on MDNA's technology, the firms said.

Terms of the deal were not disclosed.

"We anticipate that by leveraging the core expertise of both companies, many new diagnostic tests will be developed and commercialized that will lead to a better understanding of the uniqueness of a patient's cancer," Helomics President and CEO Gerald Vardzel Jr. said in a statement.

Helomics completed its restructuring to become a CRO and clinical products organization last month. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.